About: Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication
Creator	Liu, Xuefeng Wang, Weixia Li, Xintao Liu, Haiyan Liu, Xiaohui Wu, Xinghong Zhang, Pengju
Source	Elsevier; Medline; PMC
abstract	Abstract The avian coronavirus causes infectious bronchitis (IB), which is one of the most serious diseases affecting the avian industry worldwide. However, there are no effective strategies for controlling the IB virus (IBV) at present. Therefore, development of novel antiviral treatment strategies is urgently required. As reported, astragalus polysaccharides (APS) have potential antiviral effects against several viruses; however, the antiviral effect of APS against IBV remains unclear. In this study, we explored whether APS had the potential to inhibit IBV infectionby utilizing several in vitro experimental approaches. To this end, the effect of APS on the replication of IBV was examined in chicken embryo kidney (CEK) cells. Viral titers were calculated by using the plaque formation assay, and the cytotoxicity of APS was tested by utilizing a Cell Counting Kit-8 assay. The expression of viral mRNA and cytokine (IL-1β, IL-6, IL-8 and TNF-α) mRNA transcripts was determined by real-time quantitative RT-PCR(qRT-PCR). IBV titers in infected CEK cells treated with APS were significantly reduced in a dose-dependent manner, indicating that APS inhibited IBV replication in vitro. We also found that the decreased viral replication after APS treatment was associated with reduced mRNA levels of the cytokines IL-1B, IL-6, IL-8 and TNF-α. In conclusion, these results suggest that APS exhibit antiviral activities against IBV and it may represent a potential therapeutic agent for inhibiting the replication of IBV.
has issue date	2018-01-31(xsd:dateTime)
bibo:doi	10.1016/j.micpath.2017.11.026
bibo:pmid	29170045
has license	els-covid
sha1sum (hex)	b5d9ed7eac05b224c3f0f331efca338f4285ae2a
schema:url	https://doi.org/10.1016/j.micpath.2017.11.026
resource representing a document's title	Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication
has PubMed Central identifier	PMC7126552
has PubMed identifier	29170045
schema:publication	Microbial Pathogenesis
resource representing a document's body	covid:b5d9ed7eac05b224c3f0f331efca338f4285ae2a#body_text
is schema:about of	named entity 'study' named entity 'remains' named entity 'IL-8' named entity 'potential' named entity 'astragalus' named entity 'APS' named entity 'IBV' named entity 'diseases' named entity 'AVIAN INFECTIOUS BRONCHITIS VIRUS' named entity 'ASTRAGALUS' named entity 'VIRUS INFECTION' named entity 'VIRAL REPLICATION' named entity 'POLYSACCHARIDES' named entity 'INFECTIOUS BRONCHITIS' named entity 'CONTROLLING' named entity 'CEK' named entity 'POTENTIAL' named entity 'PLAQUE' named entity 'IL-8' named entity 'IBV' named entity 'IL-6' named entity 'EXAMINED' named entity 'MRNA' named entity 'TESTED' named entity 'UNCLEAR' named entity 'CYTOKINE ' named entity 'EXPERIMENTAL' named entity 'VIRAL' named entity 'EFFECTIVE' named entity 'END' named entity 'HAVE' named entity 'ACTIVITIES' named entity 'IL-1B' named entity 'REQUIRED' named entity 'WORLDWIDE' named entity 'CYTOKINES' named entity 'PRESENT' named entity 'ASSOCIATED WITH' named entity 'REGULATING' named entity 'NOVEL' named entity 'STUDY' named entity 'AFFECTING' named entity 'CELLS' named entity 'APS' named entity 'TREATMENT' named entity 'EFFECTS' named entity 'ANTIVIRAL' named entity 'AVIAN' named entity 'STRATEGIES' named entity 'INDUSTRY' named entity 'ONE OF' named entity 'THESE' named entity 'THERAPEUTIC AGENT' named entity 'ASSAY' named entity 'KIT' named entity 'VIRAL REPLICATION' named entity 'CHICKEN' named entity 'TREATED WITH' named entity 'A CELL' named entity 'VIRAL MRNA' named entity 'DEVELOPMENT' named entity 'RESULTS' named entity 'TRANSCRIPTS' named entity 'USING' named entity 'CAUSES' named entity 'DISEASES' named entity 'LEVELS' named entity 'PCR' named entity 'INDICATING' named entity 'CELL COUNTING' named entity 'AVIAN CORONAVIRUS' named entity 'EMBRYO' named entity 'CALCULATED' named entity 'FORMATION' named entity 'IN VITRO'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software